990 results about "Quinoxaline" patented technology

The present invention relates to a method of treating, reducing, inhibiting, preventing and / or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.

Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

In an organic EL device comprising organic layers between a pair of electrodes participating in at least a light emitting function, at least one organic layer contains an organic compound selected from naphthacene, tetraaryldiamine, anthracene and quinoxaline derivatives as a host material and an organic compound having a specific skeleton, typically diindeno[1,2,3-cd:1',2',3'-lm]perylene derivative as a dopant. The device is capable of light emission to a satisfactory luminance, especially in a long wavelength region, and with a chromatic purity sufficient for use in full color displays, and had a sufficient durability to sustain such improved light emission performance over a long time.

It is an object to provide a novel bipolar organic compound. In particular, it is an object to provide a bipolar organic compound excellent in thermal stability. Further, it is another object to provide a bipolar organic compound which is electrochemically stable. A quinoxaline derivative represented by a general formula (1) is provided. Further, since the quinoxaline derivative represented by the general formula (1) is bipolar, the use of the quinoxaline derivative of the present invention allows fabrication of a light-emitting element and a light-emitting device with a low driving voltage and low power consumption. Furthermore, a light-emitting element with high luminous efficiency can be obtained.

Quinoxaline compounds, compositions, methods of making them, and methods of using them in leukocyte recruitment inhibition, in modulating an H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.

The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

An organometallic compound comprising a quinoxaline structure, and having a structure represented by the following general formula (2), wherein M represents a monovalent to trivalent metal, L represents a ligand, Ar1 and Ar2 represent an aryl group in which a part of hydrogens may be substituted, and the same or different, m represents an integer of 1 to 3, n represents an integer of 0 to 2, and m-n is an integer of 1 to 3.

The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of IkappaB kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

A 6H-indolo[2,3-b]quinoxaline derivative has a structure of formula (I). R9 is a member selected from the group consisted of an aryl group having one or more substituents and a heteroaryl group having one or more substituents, and R1 to R8 are substituents. The 6H-indolo[2,3-b]quinoxaline derivative of the present invention incorporates an indole and a quinoxaline group therefore inherits good energy transfer ability from indole and good electron-injection ability from quinoxaline. The compound of the present invention may function as a host material or a dopant in the light-emitting layer. In addition, the compound of the present invention may function as hole transport material, electron transport material, hole blocking material, electron blocking material, hole injecting material or electron injecting material.

The subject invention relates to methods of treating alpha-2 adenoreceptor modulated disorders, comprising administration, to a mammal in need of such treatment, of a safe and effective amount of a compound having the following structure: wherein: (a) R is unsubstituted C1-C3 alkanyl or alkenyl; and (b) R' is selected from hydrogen; unsubstituted C1-C3 alkanyl or alkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thiol; and halo. The subject invention also relates compounds and compositions for preventing or treating of disorders modulated by alpha-2 adrenoreceptors.

The present invention is to provide quinoxaline derivatives, which have excellent electron transportation and hole blocking properties, and which can be formed into a film without being crystallized. According to the invention, quinoxaline derivatives represented by the general [formula 1] are synthesized.(wherein X and Y represent a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and R1 to R6 represent individually hydrogen, an alkyl group, an alkoxyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group. Further, an organic semiconductor device including an electroluminescent device containing the foregoing quinoxaline derivatives is formed.)

A quinoxaline-based, new bipolar organic compound is provided, and a light emitting element using the quinoxaline-based compound is demonstrated. The quinoxaline derivative of the invention has a structure in which carbon at one or both of the 2-position and the 3-position of the quinoxaline unit are bonded, via an arylene group, with an amine unit which has a substituted or unsubstituted five-membered ring or a substituted or unsubstituted condensed ring containing a five-membered ring structure. The quinoxaline-based compound was proven to possess bipolar characteristics in view of carrier transportation, which allows the fabrication of a light emitting element and an electronic appliance with a low driving voltage and low power consumption.

Compounds of Formula (I):where R1, R2, R5, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a “Substituted-Quinoxaline-Type Bridged-Piperidine Compound”), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

An optically active 2,3-bis(dialkylphosphino)pyrazine derivative represented by formula (1) is disclosed. The pyrazine derivative is preferably a quinoxaline derivative represented by formula (2). In formula (1) and (2), R1 is preferably a t-butyl or adamantyl group, and R2 is preferably a methyl group. wherein R1 is a substituted or unsubstituted, straight chain or branched alkyl group having 2 to 10 carbon atoms; R2 is a substituted or unsubstituted, straight chain or branched alkyl group having fewer carbon atoms than R1; and R3 and R4, which may be the same or different, are each a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R3 and R4 are taken together to form a saturated or unsaturated ring. wherein R1 and R2 are as defined above; and R5 is a monovalent substituent.

Provided is a novel heterocyclic compound which has excellent heat resistance and can be used as a host material for a light-emitting substance (a substance emitting fluorescence or a substance emitting phosphorescence). A light-emitting element includes a heterocyclic compound which includes one dibenzo[f,h]quinoxaline ring, one ring having a hole-transport skeleton, and two to eight benzene rings. Note that in the above structure, the molecular weight of the heterocyclic compound is greater than or equal to 564 and less than or equal to 1000.

The invention discloses a pyrazolo N-substituted dehydronorcantharidin imide derivative as well as a synthesis method, an activity test method and application thereof, belonging to the field of cantharidin derivatives. The pyrazolo N-substituted dehydronorcantharidin imide derivative has a structural general formula shown as a formula 1: in the formula 1, R1 is H, C1, F, CH3, OCH3, OH or NO2; and R2 is 2-phenyl-2H-1,2,3-triazole-4-substituent or quinoxaline-2-substituent. The novel N-substituted dehydronorcantharidin imide derivative introduces five-membered heterocyclic pyrazole rings into norcantharidin substituted arylamine and has favorable anti-tumor activity.

Ophthalmic compositions include a carrier component, an oxy-chloro component present at an amount effective in preserving the composition, and at least one additional component, e.g. a borate component and / or a glycerin component present in an amount effective to enhance a preservative efficacy of the composition. The compositions preferably also include one or more other components, such as therapeutic components, e.g., quinoxaline components, and polyanionic components effective to provide the compositions with one or more functionalities.

The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

A quinoxaline derivative expressed by the general formula (1) is provided. (Each of R1 to R12 represents one of a hydrogen atom, a halogen atom, an alkyl group, an alkoxyl group, an acyl group, a dialkyl amino group, a diarylamino group, a substituted or unsubstituted vinyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocycle group. Ar1 represents one of a substituted or unsubstituted biphenyl group and a substituted or unsubstituted terphenyl group, and Ar2 represents one of a substituted or unsubstituted phenyl group, a substituted or unsubstituted biphenyl group, a substituted or unsubstituted terphenyl group, and a substituted or unsubstituted monocyclic heterocycle group.)

A light-emitting element with low drive voltage, a light-emitting element with high current efficiency, and / or a light-emitting element with a long lifetime are / is provided. Specifically, a light-emitting element with low drive voltage, a light-emitting element with high current efficiency, and / or a light-emitting element with a long lifetime are / is provided by the use of an organic compound with a dibenzo[f,h]quinoxaline skeleton in a light-emitting layer. In a light-emitting element which includes a light-emitting layer containing an organic compound between a pair of electrodes, the organic compound has a 2,3-unsubstituted dibenzo[f,h]quinoxaline skeleton, a hole-transport skeleton selected from a substituted or unsubstituted dibenzothiophene skeleton, a substituted or unsubstituted dibenzofuran skeleton, and a substituted or unsubstituted carbazole skeleton, and an arylene skeleton, and the 2,3-unsubstituted dibenzo[f,h]quinoxaline skeleton and the hole-transport skeleton are bonded through the arylene skeleton.

Clear, high load water miscible emulsions of quinoxalinyl ester herbicides, particularly quizalofop-p-ethyl, as a single phase, translocatable composition which is free of xylene and alkylphenol ethoxylate surfactants and concentrate matrix for the active quinoxalinyl ester component at between about 9 and about 25 wt. % active concentration.

Provided herein are compounds of the formula (I): wherein R1-R8 are as described herein, R4 being phthalazinyl, pyrazinyl, pyridazinyl, or quinoxalinyl. Such compounds are particularly useful in the treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine, or dopamine.

This invention relates to compounds of the formulawherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and / or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

The invention relates to a quinoxaline unit containing organic thermally activated delayed fluorescent material and an application thereof. The organic thermally activated delayed fluorescent material, which contains a quinoxaline unit and has good light emitting performance, is obtained through carrying out multiaspect modification by taking quinoxaline with high electrophilicity as a core and constructing different D-A structures by particularly introducing fluorine atoms with high electro-withdrawing power to molecular design for the first time, so that efficient light-emitting elements are obtained, and the thinking of people that conventional fluorescent materials are free of halogens is broken through. The organic thermally activated delayed fluorescent material is simple in synthesis and high in yield and has the advantages of practical large-scale production and application. The [delta]E(S1-T1) of the organic thermally activated delayed fluorescent material is not greater than 0.65eV, so that the organic thermally activated delayed fluorescent material can be applied to the evaporation-coating of devices and can also be applied to the spin-coating of the devices. Electroluminescent elements and luminescent devices with high efficiency, high brightness, low-efficiency attenuation and low trigger voltage are provided through using the novel thermally activated delayed fluorescent material, so that the organic thermally activated delayed fluorescent material can be extensively applied to the field of organic electroluminescence.

The present invention provides a quinoxaline derivative represented by a general formula (G1). In the formula, α1 and α2 each independently represent an arylene group which has 13 or less carbon atoms forming a ring; Ar represents an aryl group which has 13 or less carbon atoms forming a ring; R1 and R6 each independently represent any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or an aryl group which has 13 or less carbon atoms forming a ring; and R2 to R5 and R7 to R10 each independently represent any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted biphenyl group.